In vitro and in vivo anticancer efficacy of the combination of actinomycin D and resveratrol.
1/5 보강
Actinomycin D (Act D) was the first FDA-approved anticancer antibiotic.
APA
Raji L, Afrin R, et al. (2026). In vitro and in vivo anticancer efficacy of the combination of actinomycin D and resveratrol.. Biochemistry and cell biology = Biochimie et biologie cellulaire, 104, 1-11. https://doi.org/10.1139/bcb-2025-0310
MLA
Raji L, et al.. "In vitro and in vivo anticancer efficacy of the combination of actinomycin D and resveratrol.." Biochemistry and cell biology = Biochimie et biologie cellulaire, vol. 104, 2026, pp. 1-11.
PMID
41506725 ↗
Abstract 한글 요약
Actinomycin D (Act D) was the first FDA-approved anticancer antibiotic. However, its widespread application was hindered by dose-limiting toxicities. In the current study, we investigated the in vitro and in vivo anticancer efficacy of the combination of Act D with resveratrol. We found that the combination of Act D and resveratrol has better in vitro efficacy than any of the single agent. We also explored the underlying mechanism by investigating the activation of the p53 pathway. Consistent with the cell growth inhibition, Act D, resveratrol, and their combination activated p53 and induced the expression of , and mRNA and proteins. The combination had better effects than any of the single agents alone. Ablation of p53 significantly protected cells and confirmed p53-dependent expression of these genes. Finally, we investigated the in vivo efficacy of these agents and their combination using xenograft model. Act D, resveratrol, and their combination significantly inhibited the growth of xenografts. The in vivo efficacy was further supported by Ki-67 expression in tumor tissues. Taken together, our findings demonstrated that although the combination of Act D and resveratrol showed better efficacy in vitro than any of the single agent, the in vivo efficacy was not improved.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.